OWC Pharmaceutical Research Corp(OTCMKTS:OWCP) has made a move over the past few months like few stocks ever do running from $0.003 lows to highs of $3.23 a share. These are the type of gains that do happen in the booming MJ sector. Since then the stock has formed a new base in the $1.25 range where it is consolidating well.
OWCP started running as pot stocks heated up going into the election. The red hot Marijuana industry has quickly turned into a multi-billion dollar massive growth market that is sweeping across the Country with many new states having legalized the drug including California, Nevada, Maine, and Massachusetts on November 8.. Medical MJ products in the U.S. alone are projected to generate up to $35 Billion by 2020.
OWC Pharmaceutical Research Corp(OTCMKTS:OWCP) through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
The Company’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.
OWCP wholly owned subsidiary, One World Cannabis (OWC) conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD and migraines. OWC is also developing a unique delivery system for the effective delivery and dosage of medical cannabis.
On September 30 OWCP announced it signed an agreement for $300,000 with Medmar LLC (“Medmar”). According to the terms of the agreement, the funds will be allocated to complete the development of the Company’s proprietary psoriasis cream;
Medmar will have exclusive right to manufacture, produce, publicize, promote and market OWC’s Licensed Products in any state in the U.S; The loan is non-interest bearing and will be repaid from royalties generated by the sale of OWC licensed products.
To Find out the inside Scoop on OWCP Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Commenting on his investment, Steve Weinstein, CEO of Medmar said, “Medmar has been anxious to advance cannabis as medicine, however US regulation makes it very difficult for companies here to actively pursue any type of development in the sector; fortunately, the environment in Israel is more favorable to the industry.”
In October OWCP announced it has completed the development of a proprietary, cannabinoid-enriched sublingual tablet (the “Tablet”) for the administration of medical cannabis.
The technology behind the Tablet is protected and provides for the ingestion of virtually any dosage of medical cannabis with a sublingual delivery mechanism, whereby the compounds are absorbed directly into the patient’s blood through oral epithelial tissue. The Tablet also enables physicians to safely and accurately monitor the dosage and treatment of each individual patient, something that is essentially impossible to do for patients who administer cannabis by smoking.
On March 21 OWCP announced the highly promising results of its topical cream efficacy tests following months of study and scientific analysis. In October 2016, OWC announced that it was in the final phase of pre-clinical efficacy testing for its topical psoriasis cream and also announced a parallel test to assess the efficacy of the formulation in treating psoriasis in human skin tissue. The recent results are highly promising, showing significant reduction of several inflammation markers specific to psoriasis.
As a result of the promising results of our psoriasis tests, our Chairman and CEO, Mr. Mordechai Bignitz, has directed OWC’s scientific team to submit an operating plan within 60 to 90 days to conduct double-blind efficacy tests of our cannabinoid-based topical cream on other skin disorders and conditions.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $185 million market valuation OWCP has $2 million cash on the books and rising debt. OWCP is an exciting story developing in small caps; the Company is developing cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWCP has quickly become an Investors favorite with ready liquidity, big momentum and a breakout chart. We will be updating on OWCP when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with OWCP.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in OWCP either long or short and we have not been compensated for this article.